FLUOROPHARMA MEDICAL, INC.
FPMI evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Market Cap:
- $7K
- Lead Asset:
- bfpet (Phase 2)
What it means
What to watch
Prepared research question
What matters most for FPMI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$7K
Cash Runway
—
Lead Asset
bfpet (Phase 2)
Next Catalyst
—
Tracking 1 pipeline candidate for FLUOROPHARMA MEDICAL, INC..
Run FLUOROPHARMA MEDICAL, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available FLUOROPHARMA MEDICAL, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is FLUOROPHARMA MEDICAL, INC.'s lead drug candidate?
FLUOROPHARMA MEDICAL, INC.'s most advanced tracked candidate is bfpet (Phase 2) for Stress-testing for patients with presumptive or proven CAD.
Who is the CEO of FLUOROPHARMA MEDICAL, INC.?
Thomas H. Tulip, Ph.D. is the chief executive officer of FLUOROPHARMA MEDICAL, INC. (FPMI).
Where is FLUOROPHARMA MEDICAL, INC. headquartered?
FLUOROPHARMA MEDICAL, INC. (FPMI) is headquartered in Montclair, NJ, United States.
What therapeutic areas does FLUOROPHARMA MEDICAL, INC. focus on?
FLUOROPHARMA MEDICAL, INC. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.